Exscien Corporation

Exscien Corporation

Primary Technology: Fusion Protein for mitochondrial DNA damage repair

President: Christine Chancery
Executive Vice President: Steve Cumbie
Chief Scientific Officer: Dr. Glenn Wilson
Scientific Advisor: Dr. Mark Gillespie (Professor and Chairman, Department of Pharmacology)

Company/Tech Description:

Exscien licensed a USA College of Medicine technology, which is a novel “fusion protein” targeting DNA repair enzymes to mitochondria. In animal and human cells, the new agents block onset of and ameliorate ongoing mtDNA damage and prevent formation of injury-propagating mtDNA fragments. As opposed to current reactive oxygen species scavenging technologies, Exscien’s fusion protein drugs will repair mtDNA damage without interfering with the positive effects of oxygen species.

Contact:

Mark Gillespie, PhD
Department of Pharmacology, College of Medicine University of South Alabama
Mobile, AL 36688
Office: (251) 460-6497 mgillesp@southalabama.edu

News Link: http://search.al.com/gillespie+AND+exscien/1/all/?date_range=all